Implications of the global increase of diabetes for tuberculosis control and patient care.
OBJECTIVE
To review the current knowledge about tuberculosis (TB) and diabetes, assessing the implication of the global increase of diabetes for TB control and patient care.


METHODS
Systematic literature review.


RESULTS
Using public databases, it can be estimated that 12.6% (95% CI 9.2-17.3%) of new TB cases in the 10 countries with the highest TB burden will be attributable to TB in 2030, a relative increase of 25.5% compared to 2010. Diabetes is associated with a higher age and body weight among patients with TB, but probably not with a specific clinical presentation of TB. Rifampicin hampers glycemic control by increasing the metabolism of most oral antidiabetic drugs, while diabetes patients may have lower concentrations of anti-TB drugs. This might be one factor contributing to higher TB treatment failure rates.


CONCLUSIONS
The global epidemic of diabetes has implications for control and treatment of TB. Prospective studies are needed to improve prevention, early detection and treatment of concomitant diabetes and TB, especially in developing countries.
Department of Pharmacology, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung, Indonesia.
Rovina
R
Ruslami
Rob E
RE
Aarnoutse
Bachti
B
Alisjahbana
Andre J A M
AJ
van der Ven
Reinout
R
van Crevel
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use; D003906:Developing Countries; D048909:Diabetes Complications / Q000453:epidemiology* / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000453:epidemiology; D004347:Drug Interactions; D058872:Epidemics; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000453:epidemiology* / Q000517:prevention & control; D014376:Tuberculosis / Q000453:epidemiology* / Q000517:prevention & control; D055815:Young Adult
D000995:Antitubercular Agents; D007004:Hypoglycemic Agents